Drug Profile
DSP 0337
Alternative Names: DSP-0337; Napabucasin-prodrugLatest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator Sumitomo Dainippon Pharma
- Developer Sumitomo Pharma
- Class Antineoplastics; Furans; Naphthoquinones; Small molecules
- Mechanism of Action Beta catenin inhibitors; Cell death stimulants; STAT3 transcription factor inhibitors; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Solid tumours